Ivabradine oxalate

• CAT Number: I029674
• CAS Number: 1086026-42-7
• Molecular Formula: C29H38N2O9
• Molecular Weight: 558.63
• Purity: 98%
• Synonyms: Ivabradine oxalate
• Solubility: To be determined
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 3-[3-[[(7S)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one;oxalic acid
• InChI: InChI=1S/C27H36N2O5.C2H2O4/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30;3-1(4)2(5)6/h12-14,16,21H,6-11,15,17H2,1-5H3;(H,3,4)(H,5,6)/t21-;/m1./s1
• InChIKey: BOHZBFAHOBOJOS-ZMBIFBSDSA-N
• SMILES: CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)C[C@H]3CC4=CC(=C(C=C34)OC)OC.C(=O)(C(=O)O)O

Ivabradine oxalate（Cat No.:I029674）is a selective inhibitor of the If (funny) current in the sinoatrial node of the heart, used primarily in the treatment of heart failure and angina. By slowing down the heart rate without affecting contractility, it helps improve cardiac efficiency and reduce symptoms of heart failure, such as shortness of breath and fatigue. Ivabradine oxalate is also prescribed to reduce hospitalizations related to chronic heart failure and is effective in patients who cannot tolerate beta-blockers. It is typically used in combination with other heart failure medications for optimal management.

Reference

1: Ide T, Ohtani K, Higo T, Tanaka M, Kawasaki Y, Tsutsui H. Ivabradine for the Treatment of Cardiovascular Diseases. Circ J. 2019 Jan 25;83(2):252-260. doi: 10.1253/circj.CJ-18-1184. Epub 2018 Dec 29. PMID: 30606942.
2: Bocchi EA, Salemi VMC. Ivabradine for treatment of heart failure. Expert Opin Drug Saf. 2019 May;18(5):393-402. doi: 10.1080/14740338.2019.1612873. Epub 2019 May 10. PMID: 31074301.
3: Komajda M. Ivabradine. Handb Exp Pharmacol. 2017;243:167-175. doi: 10.1007/164_2016_55. PMID: 27752846.
4: Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The Clinical Use of Ivabradine. J Am Coll Cardiol. 2017 Oct 3;70(14):1777-1784. doi: 10.1016/j.jacc.2017.08.038. PMID: 28958335.
5: Chiu MH, Howlett JG, Sharma NC. Initiation of ivabradine in cardiogenic shock. ESC Heart Fail. 2019 Oct;6(5):1088-1091. doi: 10.1002/ehf2.12499. Epub 2019 Jul 23. PMID: 31332966; PMCID: PMC6816060.
6: Dallapellegrina L, Sciatti E, Vizzardi E. Ivabradine and endothelium: an update. Ther Adv Cardiovasc Dis. 2020 Jan-Dec;14:1753944720934937. doi: 10.1177/1753944720934937. PMID: 32611276; PMCID: PMC7333483.
7: Tsutsui H, Momomura SI, Yamashina A, Shimokawa H, Kihara Y, Saito Y, Hagiwara N, Ito H, Yano M, Yamamoto K, Ako J, Inomata T, Sakata Y, Tanaka T, Kawasaki Y; J-SHIFT Study Investigators. Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure　- J-SHIFT Study. Circ J. 2019 Sep 25;83(10):2049-2060. doi: 10.1253/circj.CJ-19-0227. Epub 2019 Aug 8. PMID: 31391387.
8: Zhou Y, Wang J, Meng Z, Zhou S, Peng J, Chen S, Wang Q, Sun K. Pharmacology of Ivabradine and the Effect on Chronic Heart Failure. Curr Top Med Chem. 2019;19(21):1878-1901. doi: 10.2174/1568026619666190809093144. PMID: 31400267.
9: Pei H, Miao W, Xie WZ, Wang W, Zhao D, Su GH, Zhao Z. Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure. Int Heart J. 2019 Jul 27;60(4):899-909. doi: 10.1536/ihj.18-559. Epub 2019 Jul 12. PMID: 31308326.
10: Simko F, Baka T, Poglitsch M, Repova K, Aziriova S, Krajcirovicova K, Zorad S, Adamcova M, Paulis L. Effect of Ivabradine on a Hypertensive Heart and the Renin-Angiotensin-Aldosterone System in L-NAME-Induced Hypertension. Int J Mol Sci. 2018 Oct 3;19(10):3017. doi: 10.3390/ijms19103017. PMID: 30282928; PMCID: PMC6212851.